Erasca, Inc. (ERAS)
| Market Cap | 2.20B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -96.02M |
| Shares Out | 116.14M |
| EPS (ttm) | -0.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 27 |
| Last Price | $18.96 |
| Previous Close | $18.85 |
| Change ($) | 0.11 |
| Change (%) | 0.58% |
| Day's Open | 19.00 |
| Day's Range | 18.20 - 19.31 |
| Day's Volume | 152,533 |
| 52-Week Range | 14.51 - 20.27 |
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pat...
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pat...
Erasca, Inc. has filed to go public with an IPO on the NASDAQ.
About ERAS
Erasca is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS and the MAPK pathway account for approximately 5.5 million new cases of cancer worldwide per year. We have assembled what we believe to be the deepest, wholly-owned or controlled RAS/MAPK pathway-focused pipeline in the industry, comprising 11 modality-agnostic programs aligned with our three therapeutic strategies of: (1) targeting key ... [Read more...]
| Industry Pharmaceutical Preparations | IPO Date Jul 16, 2021 |
| CEO Jonathan E. Lim, M.D. | Employees 102 |
| Stock Exchange NASDAQ | Ticker Symbol ERAS |